A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.

被引：0
|
作者：
Papadopoulos, K
Mendelson, D
Preston, GG
Lopez, AM
Ricart, AD
Schwartz, G
Needle, MN
Gordon, MS
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[3] Arizona Canc Ctr, Scottsdale, AZ USA
[4] Brooke Army Med Ctr, San Antonio, TX USA
[5] Celgene, Summit, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9116S / 9116S
页数：1
相关论文
共 50 条
  • [1] Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.
    Tan, BR
    Read, W
    Bergeron, K
    Fracasso, PM
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [2] Phase I trial of weekly irinotecan plus docetaxel in patients with advanced solid tumors.
    Font, A
    Sánchez, JM
    Guillot, M
    Abad, A
    Taron, M
    Margelí, M
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [3] Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
    Marchetti, Serena
    Stuurman, Frederik
    Koolen, Stijn
    Moes, Johannes
    Hendrikx, Jeroen
    Thijssen, Bas
    Huitema, Alwin D. R.
    Nuijen, Bastiaan
    Rosing, Hilde
    Keessen, Marianne
    Voest, Emile E.
    Mergui-Roelvink, M.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors
    Kouroussis, C
    Androulakis, N
    Vamvakas, L
    Kalykaki, A
    Spiridonakou, S
    Kentepozidis, N
    Saridaki, Z
    Xiropoulou, E
    Georgoulias, V
    ONCOLOGY, 2005, 69 (03) : 202 - 207
  • [5] Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
    S. Kalmadi
    M. Davis
    A. Dowlati
    S. O’Keefe
    M. Cline-Burkhardt
    R. J. Pelley
    E. Borden
    R. Dreicer
    R. Bukowski
    T. Mekhail
    Investigational New Drugs, 2007, 25 : 211 - 216
  • [6] Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
    Kalmadi, S.
    Davis, M.
    Dowlati, A.
    O'Keefe, S.
    Cline-Burkhardt, M.
    Pelley, R. J.
    Borden, E.
    Dreicer, R.
    Bukowski, R.
    Mekhail, T.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (03) : 211 - 216
  • [7] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [8] A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
    Chan, Nancy
    Portal, Daniella E.
    Moss, Rebecca Anne
    Silk, Ann W.
    Stein, Mark N.
    Aisner, Joseph
    Malhotra, Jyoti
    Shih, Weichung
    Lin, Hongxia
    Kane, Michael P.
    Mehnert, Janice M.
    Tan, Antoinette R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
    Font, A
    Sanchez, JM
    Rosell, R
    Taron, M
    Martinez, E
    Guillot, M
    Manzano, JL
    Margeli, M
    Barnadas, A
    Abad, A
    LUNG CANCER, 2002, 37 (02) : 213 - 218
  • [10] Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Fakih, MG
    Creaven, PJ
    Ramnath, N
    Trump, D
    Javle, M
    Strychor, S
    Repinski, TV
    Zamboni, BA
    Schwarz, JK
    French, RA
    Zamboni, WC
    CLINICAL CANCER RESEARCH, 2005, 11 (16) : 5942 - 5949
12345